Sanofi and POZEN Sign Commercial Agreement for PA8140/PA32540 Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sanofi and POZEN Sign Commercial Agreement for PA8140/PA32540 Tablets



Sanofi and the biopharmaceutical company POZEN, have signed a license agreement for the commercialization of POZEN's tablets combining immediate-release omeprazole, a proton pump inhibitor, and enteric-coated aspirin in a single tablet (i.e, PA), PA8140 and PA32540. Under the agreement, Sanofi will have rights to commercialize all PA combinations that contain 325 mg or less of enteric-coated aspirin in the United States. POZEN will receive an upfront payment of $15 million and be eligible for precommercial milestone payments of up to $20 million and other future milestone payments and royalties on product sales.

Sanofi US will have responsibility for all sales, marketing, ongoing manufacturing, and future development for the licensed PA products in the US. POZEN will retain responsibility for obtaining approval of the new drug application (NDA), after which time POZEN will transfer the NDA to Sanofi US. The NDA was submitted in March 2013 and accepted for filing in May 2013 by FDA.

Source: Sanofi

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here